Effect of Melatonin on Cardiometabolic Risk- FULL
Study Description
“Effect of Melatonin on Cardiometabolic Risk- FULL”
In a 12 week double-blind, placebo-controlled randomized trial, 120 subjects with obesity (BMIa?Y30 kg/m2) and pre-diabetes (HbA1c, 5.7-6.4%) will be randomly assigned 1:1 to receive either placebo or 2 mg of controlled-release melatonin, taken orally every evening 1 hour before bed. The investigators will assess melatonin's effect on insulin sensitivity by performing a hyperinsulinemic euglycemic glucose clamp and I2-islet cell function measured using a hyperglycemic clamp, as a primary endpoint. The investigator will also evaluating melatonin supplementation's effect on mean 24-hour ambulatory blood pressure, nocturnal blood pressure, and potential intermediates including endothelial function using brachial ultrasound, catecholamine production using 24-hour epinephrine and norepinephrine excretion, and renin-angiotensin system activation using measurements of plasma renin activity, angiotensin II, and urine aldosterone excretion. The final endpoint will be to evaluate melatonin supplementation's effect on cellular cytokine and CC family chemokine expression as well as high sensitivity C-reactive protein, IL-6, and TNF-I?. There will be a 24 week cohort phase as an extension of the trial. This will be an open-label prospective study of 50 subjects recruited from the trial who will take 2 mg of controlled-release melatonin nightly for 24 weeks after completion of the 12-week trial. At the end of the cohort-phase (36 weeks after entry in the trial), the investigators will again assess the extended use of melatonin supplementation on 24-hour BP, and glycemic control (HbA1, fasting glucose).
Location
Methods
Pharmaceutical medication involved
Patients and healthy individuals accepted
Drug - Melatonin
Circadin, controlled release melatonin tablet 2mg by mouth each day before bedtime for 12 weeks
Drug - Placebo
placebo tablet identical to circadian
Additional Information
Official Study Title
Effect of Melatonin on Cardiometabolic Risk- FULL
Clinical Trial ID
NCT02681887
ParticipAid ID
mbkXvd
